← Eichor
Study identifier: NCT06897228 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

PANK-003 Cell Injection Combined with Standard Adjuvant Chemotherapy After Surgery in Patients with Solid Tumors

Condition: Solid Tumors, Adult  ·  Sponsor: Shenzhen Celconta Life Science Co., Ltd.

PhasePhase 1
Planned participants18
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

A single-center, single-arm, dose-escalation exploratory clinical trial on the safety and efficacy of PANK-003 cell injection(Peripheral blood-derived allogeneic natural killer cells )combined with standard adjuvant chemotherapy after surgery in patients with solid tumors

This description comes directly from the study's public registry record.

Talk to the study team

Baozhong Li  ·  139372338883  ·  libaozhong99@126.com

Always discuss trial participation with your own doctor first.

Locations (1)

AnYang Tumor HospitalAnyang, Henan, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06897228